688506 百利天恒
已收盘 05-15 15:00:00
资讯
新帖
简况
百利天恒(688506.SH)：SI-B036双特异性抗体注射液获批在晚期实体瘤中开展临床试验
智通财经 · 05-14 17:21
百利天恒(688506.SH)：SI-B036双特异性抗体注射液获批在晚期实体瘤中开展临床试验
百利天恒（688506）披露2025年年度股东会会议资料，5月13日股价上涨0.57%
证券之星 · 05-13 18:20
百利天恒（688506）披露2025年年度股东会会议资料，5月13日股价上涨0.57%
恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议
21世纪经济报道 · 05-13 08:02
恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议
百利天恒董秘空缺超三个月 董事长暂代职
财中社 · 05-12
百利天恒董秘空缺超三个月 董事长暂代职
百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组
证券之星 · 05-12
百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组
百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准
南方财经网 · 05-12
百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准
【机构调研记录】东吴基金调研百利天恒
证券之星 · 05-07
【机构调研记录】东吴基金调研百利天恒
每周股票复盘：百利天恒（688506）股东户数增34.99%，一季报营收增40.25%
证券之星 · 05-02
每周股票复盘：百利天恒（688506）股东户数增34.99%，一季报营收增40.25%
8亿美元首付款“药效”过期，百利天恒2025年净亏超10亿元
北京商报 · 04-28
8亿美元首付款“药效”过期，百利天恒2025年净亏超10亿元
百利天恒2026年一季度归母净利润约亏损7.75亿元
央广财经 · 04-27
百利天恒2026年一季度归母净利润约亏损7.75亿元
每周股票复盘：百利天恒（688506）现1笔大宗交易
证券之星 · 04-26
每周股票复盘：百利天恒（688506）现1笔大宗交易
4月21日百利天恒现1笔大宗交易 机构净卖出354.4万元
证券之星 · 04-21
4月21日百利天恒现1笔大宗交易 机构净卖出354.4万元
每周股票复盘：百利天恒（688506）股东会通过外汇衍生品交易议案
证券之星 · 04-19
每周股票复盘：百利天恒（688506）股东会通过外汇衍生品交易议案
百利天恒（688506）披露关于开展外汇衍生品交易业务的议案获临时股东大会审议通过，4月16日股价下跌0.37%
证券之星 · 04-16
百利天恒（688506）披露关于开展外汇衍生品交易业务的议案获临时股东大会审议通过，4月16日股价下跌0.37%
百利天恒一持股5%以上股东完成减持计划；博瑞医药实控人提名女儿为董事｜医药早参
每日经济新闻 · 04-02
百利天恒一持股5%以上股东完成减持计划；博瑞医药实控人提名女儿为董事｜医药早参
百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准
南方财经网 · 04-01
百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准
百利天恒（688506）披露归还临时补充流动资金的募集资金公告，3月26日股价下跌3.09%
证券之星 · 03-26
百利天恒（688506）披露归还临时补充流动资金的募集资金公告，3月26日股价下跌3.09%
百利天恒（688506）1187.38万股限售股将于3月25日解禁，占总股本2.88%
证券之星 · 03-25
百利天恒（688506）1187.38万股限售股将于3月25日解禁，占总股本2.88%
百利天恒（688506）披露BL-ARC002获晚期实体瘤临床试验批准通知书，3月23日股价下跌4.89%
证券之星 · 03-23
百利天恒（688506）披露BL-ARC002获晚期实体瘤临床试验批准通知书，3月23日股价下跌4.89%
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
智通财经 · 03-22
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是知识产权收入、化药制剂、中成药制剂。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":257.01,"timestamp":1778828400000,"preClose":258.75,"halted":0,"volume":1398012,"delay":0,"changeRate":-0.0067,"floatShares":413000000,"shares":413000000,"eps":-3.1408,"marketStatus":"已收盘","change":-1.74,"latestTime":"05-15 15:00:00","open":258.52,"high":261.91,"low":254.5,"amount":360000000,"amplitude":0.0286,"askPrice":257.01,"askSize":0,"bidPrice":256.58,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-3.1408,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":258.75,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":284.63,"lowLimit":232.88,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":18.8,"roa":"--","roe":"--","epsLYR":-2.61,"committee":0.407407,"marketValue":106113000000,"turnoverRate":0.0034,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-18。","afterMarket":{"amount":0,"volume":0,"close":257.01,"buyVolume":0,"sellVolume":0,"time":1778830437559,"indexStatus":"已收盘 05-15 15:30:00","preClose":258.75},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1778832000000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":106113000000},"requestUrl":"/m/hq/s/688506/","defaultTab":"news","newsList":[{"id":"2635379062","title":"百利天恒(688506.SH)：SI-B036双特异性抗体注射液获批在晚期实体瘤中开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635379062","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635379062?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:21","pubTimestamp":1778750492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新生物药SI-B036双特异性抗体注射液的药物临床试验获得批准，同意该品单药在晚期实体瘤中开展临床试验。据悉，SI-B036双特异性抗体注射液是公司自主研发的全球领先的特异性增强双特异性抗体平台(SEBA平台)的产品之一，SEBA分子不仅可以提高靶向性和抗肿瘤活性，还可以最大限度地减少脱靶效应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4082","02615","688506","BK4211","BK0239","SI","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635783831","title":"百利天恒（688506）披露2025年年度股东会会议资料，5月13日股价上涨0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635783831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635783831?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:20","pubTimestamp":1778667610,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，百利天恒报收于264.6元，较前一交易日上涨0.57%，最新总市值为1092.46亿元。公司于近日披露《四川百利天恒药业股份有限公司2025年年度股东会会议资料》。公告显示，四川百利天恒药业股份有限公司召开2025年年度股东会，审议2025年度董事会工作报告、利润分配方案、年度报告及其摘要、2026年度董事薪酬、续聘会计师事务所、担保额度预计及董事及高级管理人员薪酬管理制度等议案，并听取独立董事述职报告和高级管理人员薪酬方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300034335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221419","title":"恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221419","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635221419?lang=zh_cn&edition=full","pubTime":"2026-05-13 08:02","pubTimestamp":1778630577,"startTime":"0","endTime":"0","summary":"政策动向国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133735150673.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735150673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2461242641.AUD","LU1989772923.USD","LU0359201612.USD","LU1064130708.USD","LU1997245094.SGD","BK0196","LU0868494617.USD","LU2097828805.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","LU2023250843.SGD","LU1917777945.USD","BK0060","LU1162221912.USD","LU1061106388.HKD","BK4516","LU0203347892.USD","LU0130517989.USD","BK0012","LU0965508806.USD","LU1037948541.HKD","LU1116320737.USD","LU1116320901.HKD","IE00BJT1NW94.SGD","IE00BLSP4239.USD","LU1291159041.SGD","LU1093756325.SGD","LU2112291526.USD","SG9999014567.USD","LU0942090050.USD","LU1093756168.USD","LU1934455194.USD","LU0006306889.USD","SG9999014575.USD","LU0859254822.USD","BK4550","LU0405327148.USD","IE00BN8TJ469.HKD","SG9999014542.SGD","LU1585245621.USD","LU1699723380.USD","LU0965509283.SGD","LU1997244956.HKD","LU2360032135.SGD","LU1066051811.HKD","01276","BK0183","LU2324357040.USD","LU0965509101.SGD","BK0028","SG9999015358.SGD","LU0106261372.USD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0477156953.USD","SG9999013999.USD","BK1191","LU0861579265.USD","IE00B4R5TH58.HKD","BK4534","LU0265550946.USD","BK4585","LU1430594728.SGD","LU1066051225.USD","IE00BLSP4452.SGD","LU1328615791.USD","301206","IE0002141913.USD","LU1941712264.USD","LU0070302665.USD","IE00B2B36J28.USD","LU1934455863.HKD","LU2495084118.USD","LU2543165471.USD","LU2097828474.EUR","SG9999001440.SGD","002022","LU1023059063.AUD","LU0266013472.USD","LU2097828714.EUR","LU1934455277.USD","LU2488822045.USD","LU1066051498.USD","LU1969619763.USD","LU0238689110.USD","MRK","LU2361044865.SGD","LU2148510915.USD","SG9999014559.SGD","LU1989772840.SGD","LU0320765489.SGD","LU0648001328.SGD","LU2580892862.HKD","SG9999002224.SGD","IE00BFTCPJ56.SGD","LU0359202008.SGD","IE00BBT3K403.USD","LU2361045086.USD","LU2361044949.HKD","LU1781817850.SGD","LU0122379950.USD","LU2125154778.USD","LU2491050154.USD","LU1066053197.SGD","LU2097828631.EUR","IE00BSNM7G36.USD","LU0203345920.USD","LU0965509010.AUD","LU0868494708.USD","BK4588","LU1255011170.USD","LU1571399168.USD","LU0980610538.SGD","LU1146622755.USD","LU1929549753.HKD","LU1064131003.USD","LU0359201885.HKD","IE00B1BXHZ80.USD","BK0188","LU2023250504.SGD","688506","LU1035773651.USD","LU1820825898.SGD","LU0234572021.USD","LU1037948897.HKD","LU0265550359.USD","LU2106854487.HKD","SG9999002232.USD","LU1997245177.USD","LU0432979614.USD","SG9999001176.SGD","LU1069347547.HKD","BK0239","SG9999015341.SGD","LU0289739699.SGD","LU1989771016.USD","LU2289578879.USD","LU2580892789.USD","LU1974910355.USD","LU0208291251.USD","LU2357627491.SGD","SG9999001176.USD","LU0058720904.USD","LU0320765646.SGD","LU2089984988.USD","LU1201861249.SGD","LU0405327494.USD","LU0211331839.USD","IE0009355771.USD","LU2125154935.USD","LU1941712348.USD","BK4559","600276","BK4533","LU1023057109.AUD","LU1580142542.USD","LU1057294990.SGD","LU1655091616.SGD","LU0985320562.USD","LU2328871848.SGD","LU2491050071.SGD","LU2468319806.SGD","LU2097828557.USD","LU2491049909.HKD","LU0098860793.USD","BK4007","LU0130102774.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292337","title":"百利天恒董秘空缺超三个月 董事长暂代职","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292337","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634292337?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:35","pubTimestamp":1778578500,"startTime":"0","endTime":"0","summary":"5月12日，百利天恒（688506）发布公告，因董事会秘书陈英格因个人原因辞职，现由公司董事、高级管理人员张苏娅代行董事会秘书职责。张苏娅代行职责已满三个月，因公司尚未完成董事会秘书的聘任工作，自2026年5月13日起，公司法定代表人、董事长、总经理朱义代行董事会秘书职责，直至新董事会秘书聘任完成。公司将尽快完成董事会秘书的聘任工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734572276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634529442","title":"百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2634529442","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634529442?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:28","pubTimestamp":1778578101,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200029763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629466","title":"百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629466","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634629466?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:18","pubTimestamp":1778577480,"startTime":"0","endTime":"0","summary":"南财智讯5月12日电，百利天恒公告，iza-bren（EGFR×HER3双抗ADC）收到国家药品监督管理局《药物临床试验批准通知书》（通知书编号：2026LP01442），同意该药开展联合小分子靶向药物用于治疗驱动基因阳性的局部晚期或转移性非小细胞肺癌的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734555430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","91194","ADC","BK4231","02615","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633169120","title":"【机构调研记录】东吴基金调研百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2633169120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633169120?lang=zh_cn&edition=full","pubTime":"2026-05-07 08:01","pubTimestamp":1778112076,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月6日披露的机构调研信息，东吴基金近期对1家上市公司进行了调研，相关名单如下：1）百利天恒 调研纪要：在2026年3月丹麦哥本哈根举行的欧洲肺癌大会上，公司iza-bren联合斯鲁利单抗用于一线治疗广泛期小细胞肺癌的临床研究成果，成功入选大会口头报告。旗下最近一年表现最佳的公募基金产品为东吴阿尔法灵活配置混合A，最新单位净值为2.87，近一年增长200.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700003910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647834","title":"每周股票复盘：百利天恒（688506）股东户数增34.99%，一季报营收增40.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647834","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632647834?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:05","pubTimestamp":1777665914,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，百利天恒报收于272.74元，较上周的284.04元下跌3.98%。本周，百利天恒4月28日盘中最高价报287.37元。本周关注点股本股东变化：截至2026年3月31日股东户数为7777.0户，较上期增加34.99%。业绩披露要点百利天恒2026年一季报显示，公司主营收入为9458.68万元，同比增长40.25%；归母净利润为-7.75亿元，同比下降45.75%；扣非净利润为-8.3亿元，同比下降48.87%。2025年年度报告摘要显示，公司代码688506，股票简称百利天恒。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630563379","title":"8亿美元首付款“药效”过期，百利天恒2025年净亏超10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630563379","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630563379?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:53","pubTimestamp":1777366400,"startTime":"0","endTime":"0","summary":"从业绩狂欢到亏损泥潭，百利天恒上演了一场业绩“变脸”。4月28日晚间，百利天恒披露2025年年报，公司全年实现营业收入25.2亿元，同比下降56.72%；净亏损10.54亿元，而上年同期为盈利37.08亿元。业绩骤降的核心原因在于，2024年公司收到BMS的8亿美元首付款，而2025年仅确认2.5亿美元里程碑付款，一次性授权收入大幅缩水，直接将公司打回亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283722305488.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283722305488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","02615","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630318542","title":"百利天恒2026年一季度归母净利润约亏损7.75亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630318542","media":"央广财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630318542?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:34","pubTimestamp":1777300487,"startTime":"0","endTime":"0","summary":"4月27日晚间，百利天恒（688506.SH）发布一季度业绩公告。2026年第一季度营收约9459万元，同比增加40.25%；归属于上市公司股东的净利润亏损约7.75亿元，基本每股收益亏损1.88元。上年同期营收约6744万元，归属于上市公司股东的净利润亏损约5.31亿元，基本每股收益亏损1.33元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720826355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630180484","title":"每周股票复盘：百利天恒（688506）现1笔大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2630180484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630180484?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:14","pubTimestamp":1777144452,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，百利天恒（688506）报收于284.04元，较上周的298.39元下跌4.81%。本周，百利天恒4月21日盘中最高价报313.0元。4月24日盘中最低价报282.4元。百利天恒当前最新总市值1172.73亿元，在化学制药板块市值排名3/150，在两市A股市值排名165/5200。本周关注点来自交易信息汇总：4月21日百利天恒现1笔大宗交易，机构净卖出354.4万元交易信息汇总4月21日百利天恒现1笔大宗交易，机构净卖出354.4万元以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629084154","title":"4月21日百利天恒现1笔大宗交易 机构净卖出354.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629084154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629084154?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:33","pubTimestamp":1776764011,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日百利天恒发生大宗交易，交易数据如下：大宗交易成交价格296元，成交1.2万股，成交金额354.4万元，买方营业部为民生证券股份有限公司苏州分公司，卖方营业部为机构专用。近三个月该股共发生2笔大宗交易，合计成交209.0手。该股在过去半年内已有共计3.1亿股限售解禁股上市，占公司总股本的75.08%。截至2026年4月21日收盘，百利天恒报收于296.0元，下跌1.34%，换手率0.38%，成交量1.55万手，成交额4.7亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100039742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628756362","title":"每周股票复盘：百利天恒（688506）股东会通过外汇衍生品交易议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2628756362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628756362?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:21","pubTimestamp":1776532867,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百利天恒报收于298.39元，较上周的303.78元下跌1.77%。本周，百利天恒4月15日盘中最高价报314.9元。本周关注点公司公告汇总：百利天恒2026年第二次临时股东会审议通过《关于开展外汇衍生品交易业务的议案》，表决同意股数占比达99.9985%。公司公告汇总四川百利天恒药业股份有限公司于2026年4月16日召开2026年第二次临时股东会，会议由董事会召集，董事长朱义主持，采用现场与网络投票结合方式召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627621996","title":"百利天恒（688506）披露关于开展外汇衍生品交易业务的议案获临时股东大会审议通过，4月16日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627621996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627621996?lang=zh_cn&edition=full","pubTime":"2026-04-16 22:08","pubTimestamp":1776348498,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘，百利天恒报收于312.7元，较前一交易日下跌0.37%，最新总市值为1291.06亿元。该股当日开盘308.5元，最高313.78元，最低302.09元，成交额达5.69亿元，换手率为0.44%。近日，四川百利天恒药业股份有限公司召开2026年第二次临时股东会，审议通过了《关于开展外汇衍生品交易业务的议案》。公告显示，本次股东会于2026年4月16日以现场与网络投票相结合方式召开，同意股数占出席会议有表决权股份总数的99.9985%，反对和弃权比例极低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600043152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","02615","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624408215","title":"百利天恒一持股5%以上股东完成减持计划；博瑞医药实控人提名女儿为董事｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2624408215","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624408215?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:00","pubTimestamp":1775084407,"startTime":"0","endTime":"0","summary":"｜2026年4月2日星期四｜NO.1百利天恒持股5%以上股东OAPIII（HK）Limited减持股份计划完成4月1日，百利天恒公告，因自身资金需求，OAPIII（HK）Limited拟通过集中竞价方式减持公司股份不超过4128738股，减持比例不超过公司总股本的1.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023692459372.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023692459372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1574","02615","688506","91194","BK0239","688166","BK1515","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624359417","title":"百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624359417","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624359417?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:09","pubTimestamp":1775038191,"startTime":"0","endTime":"0","summary":"南财智讯4月1日电，百利天恒公告，iza-bren（EGFR×HER3双抗ADC）收到国家药品监督管理局签发的2个《药物临床试验批准通知书》（编号：2026LP00924、2026LP00979），同意其开展两项II/III期临床试验：联合阿比特龙和奥拉帕利、联合奥拉帕利用于去势抵抗性前列腺癌；联合贝伐珠单抗±化疗、联合奥拉帕利±贝伐珠单抗±化疗用于晚期卵巢癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692049453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","ADC","BK4080","91194","02615","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622866571","title":"百利天恒（688506）披露归还临时补充流动资金的募集资金公告，3月26日股价下跌3.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622866571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622866571?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:12","pubTimestamp":1774534343,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，百利天恒报收于255.0元，较前一交易日下跌3.09%，最新总市值为1052.83亿元。该股当日开盘263.37元，最高270.5元，最低253.69元，成交额达3.56亿元，换手率为0.33%。近日，四川百利天恒药业股份有限公司发布《关于归还临时补充流动资金的募集资金的公告》。截至2026年3月26日，公司已将上述6,000万元全部归还至募集资金专用账户，使用期限未超期，并已通知保荐机构和保荐代表人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622901238","title":"百利天恒（688506）1187.38万股限售股将于3月25日解禁，占总股本2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622901238","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622901238?lang=zh_cn&edition=full","pubTime":"2026-03-25 08:15","pubTimestamp":1774397757,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，百利天恒于3月25日将有1187.38万股限售股份解禁，为公司定向增发机构配售股份，占公司总股本2.88%。最近一年内，该股累计解禁3.09亿股，占总股本的74.82%。百利天恒主营业务：药品的研发、生产与营销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500010489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621977497","title":"百利天恒（688506）披露BL-ARC002获晚期实体瘤临床试验批准通知书，3月23日股价下跌4.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621977497","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621977497?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:56","pubTimestamp":1774259767,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，百利天恒报收于258.2元，较前一交易日下跌4.89%，最新总市值为1066.04亿元。该股当日开盘265.0元，最高268.0元，最低254.9元，成交额达3.39亿元，换手率为0.32%。四川百利天恒药业股份有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司自主研发的创新药BL-ARC002注射液开展晚期实体瘤的临床试验。药品从研发到上市存在周期长、环节多、高风险等特点，需完成临床试验并经审评审批后方可上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300028289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621371933","title":"百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621371933?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:41","pubTimestamp":1774165288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新药BL-ARC002注射液的药物临床试验获得批准。公告称，BL-ARC002通过抗体介导的精准靶向递送技术及放射性核素强大的肿瘤杀伤能力，与传统放射性核素偶联药物相比，具有更强的靶点特异性、更高的肿瘤富集性，并有望展现出更好的抗耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4023","159992","LU0757428866.USD","06978","02615","LU1815336091.USD","BK1161","BK1574","BL","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778869103940,"stockEarnings":[{"period":"1week","weight":-0.0329},{"period":"1month","weight":-0.1811},{"period":"3month","weight":-0.1045},{"period":"6month","weight":-0.3084},{"period":"1year","weight":-0.0355},{"period":"ytd","weight":-0.2045}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7777人(较上一季度增加34.99%)","perCapita":"53089股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是知识产权收入、化药制剂、中成药制剂。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}